|
NeuroStar TMS Therapy® Receives
Prestigious Popular Science Award
Innovative device for the treatment of depression named one
of 2009’s “Best of What’s New”
Malvern, PA [November 12, 2009]
Quick Facts
• Neuronetics’ NeuroStar® Transcranial Magnetic Stimulation
(TMS) Therapy has been selected by Popular Science as one of the
“Best of What's New” in the health category for 2009, announced
in November.
• NeuroStar TMS Therapy is the first and only non-systemic (does
not circulate in the bloodstream) and non-invasive (does not
involve surgery) depression treatment cleared by the FDA.
• NeuroStar is effective and safe in the treatment of
depression; it provides a new and unique option for the millions
of depressed patients who have not benefited from prior
antidepressant medications*.
• Prior to the availability of NeuroStar TMS Therapy, many
depressed patients without improvement to antidepressants had
only limited options, including complex and often unproven
regimens of multiple drugs, or for the more severe cases,
invasive procedures.
o Unlike these alternatives, NeuroStar TMS Therapy does not
cause systemic side effects such as weight gain, sexual
dysfunction, nausea, dry mouth, or sedation.
Spokespeople Comments
“We are very proud to have our NeuroStar TMS Therapy system
honored as a recipient of this year’s Popular Science Best of
What’s New Award. The announcement is a great testament to the
numerous researchers, engineers, designers, and clinicians who
have been working tirelessly to bring this innovative medical
device to the millions of people in need of a new treatment
option for depression,” said Neuronetics’ President and CEO,
Bruce Shook.
“For 22 years, Popular Science has honored the innovations that
surprise and amaze us − those that make a positive impact on our
world today and challenge our views of what’s possible in the
future.” said Mark Jannot, Editor-in-Chief of Popular Science.
“The ‘Best of What’s New’ Award is the magazine’s top honor, and
the 100 winners − chosen from among thousands of entrants −
represent the highest level of achievement in their fields.”
NeuroStar TMS Therapy: Key Facts
• NeuroStar TMS Therapy was cleared by the FDA in October 2008.
NeuroStar TMS Therapy is specifically indicated for the
treatment of Major Depressive Disorder in adult patients who
have failed to achieve satisfactory improvement from one prior
antidepressant medication at or above the minimal effective dose
and duration in the current episode.
• In an open-label clinical trial, which is most like real world
clinical practice, approximately 1 in 2 patients experienced
significant improvement in symptoms, and 1 in 3 experienced
complete symptom resolution.
• There were no systemic side effects observed with TMS Therapy,
such as weight gain and sexual dysfunction. The most common
adverse events related to treatment were scalp pain or
discomfort at the treatment area during active treatments.
NeuroStar TMS Therapy: How it Works
• Treatment with NeuroStar TMS Therapy activates nerve cells in
an area of the brain that is linked to depression, by delivering
highly focused MRI-strength magnetic field pulses.
• The treatment is a 40-minute outpatient procedure that is
performed under supervision of a psychiatrist, does not require
anesthesia or sedation, and is administered daily for 4-6 weeks.
NeuroStar TMS Therapy may not be effective for all patients with
depression and is contraindicated in patients with metallic
implants in or around the head.
NeuroStar TMS Therapy: Availability
Treatment with NeuroStar TMS Therapy is available by
prescription only from a psychiatrist. It is available or will
soon be available at more than 100 treatment centers in the US.
For specific information on treatment locations with NeuroStar
TMS Therapy, please visit
www.NeuroStarTMS.com or call the Neuronetics Customer
Service Center at (877) 600-7555.
Facts About Depression
Depression can affect anyone, regardless of race, age, gender or
lifestyle.
• 33 to 35 million Americans reported being diagnosed with
depression within their lifetime.
• 13 to 14 million adults reported being diagnosed with
depression within the past 12 months.
• Women are affected almost twice as often as men.
• The economic burden of depression in 2000 was estimated at
$83.1 billion in the US.
• Researchers estimate that by the year 2020, depression will be
the second leading cause of disability worldwide.
• Nearly 30% of patients with depression do not benefit from or
are intolerant of antidepressant medication therapy.
About Neuronetics
Neuronetics, Inc. is a privately-held medical device company
focused on developing non-invasive therapies for psychiatric and
neurological disorders using MRI-strength magnetic field pulses.
Based in Malvern, PA, Neuronetics is the leader in the
development of TMS Therapy, a non-invasive form of
neuromodulation. For more information, please visit
www.neuronetics.com.
Media Contact
Nancie Steinberg
Chamberlain Communications
Ph: 212-884-0667
E-mail: nsteinberg @chamberlainpr.com
*NeuroStar TMS Therapy® is indicated for the treatment of Major
Depressive Disorder in adult patients who have failed to achieve
satisfactory improvement from one prior antidepressant
medication at or above the minimal effective dose and duration
in the current episode.
NeuroStar®, NeuroStar TMS Therapy®, and TMS Therapy® are
registered trademarks of Neuronetics, Inc.
|
